Article
UPDATED: A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Th
Rating:
0.0
Views:
160
Likes:
1
Library:
1
Illumina is going to have a lot of work to do to prove Grail was worth those $8 billion. Today, Exact Sciences announced that it will acquire Thrive, Grail's chief rival among the early cancer detection startups, for a sizeable but relatively moderate $2.15 billion. The yawning gap in part
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value